5,5-二甲基丙二酰脲 | 24448-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5,5-二甲基丙二酰脲
• 中文别名: 5,5-二甲基巴比土酸；5,5-二甲基巴比妥酸
• 英文名称: 5,5-dimethylbarbituric acid
• 英文别名: dimethylbarbituric acid；5,5-dimethyl-1,3-diazinane-2,4,6-trione
• CAS: 24448-94-0
• 化学式: C₆H₈N₂O₃
• 分子量: 156.141
• InChiKey: LAOZSCRCYVBSJA-UHFFFAOYSA-N

物化性质

• 熔点：
  278-279 °C
• 沸点：
  280.35°C (rough estimate)
• 密度：
  1.3889 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933540000

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 5,5-Dimethylbarbituric acid
CAS-No. : 24448-94-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 5,5-Dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione
Formula : C6H8N2O3
Molecular Weight : 156,14 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 278 - 279 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5,5-二甲基丙二酰脲 在 samarium diiodide 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 26.0h， 生成 (E)-4,4-dimethyl-2-(4-(naphthalen-1-yl)but-3-enyl)-5-(naphthalen-1-ylmethyl)-6,7-dihydropyrrolo[1,2-c]pyrimidine-1,3(2H,4H)-dione
  参考文献：
  名称：

  电子转移至酰胺型羰基化合物引发的自由基杂环和杂环级联反应

  摘要：

  通过使用SmI 2 -H 2 O将电子转移至酰胺型羰基引发的自由基杂环化反应，可以直接进入含有桥头氮中心的双环杂环骨架。此外，由酰胺型羰基还原引起的第一个自由基杂环级联反应提供了新颖，复杂的四环结构，其中包含五个连续的立体中心，并具有出色的非对映控制性。

  DOI：

  10.1002/anie.201708354
• 作为产物：
  描述：

  二甲基丙二酸二乙酯 在 三氯氧磷 作用下， 生成 5,5-二甲基丙二酰脲
  参考文献：
  名称：

  Thorne, Journal of the Chemical Society, 1881, vol. 39, p. 545

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-氨基-5-氯-3-硝基吡啶 在 4-二甲氨基吡啶 、 Oxone 、 N-氯代丁二酰亚胺 、 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 5,5-二甲基丙二酰脲 、 tin(II) chloride dihdyrate 、 sodium hydride 、 溶剂黄146 、 sodium iodide 、 potassium hydroxide 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 N,N-二甲基乙酰胺 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 76.0h， 生成 ethyl cis-4-((6-chloro-5-(4-(pyrrolidin-1-yl)phenyl)-1H-imidazo[4,5-b]pyridin-2-yl)oxy)cyclohexane-1-carboxylate
  参考文献：
  名称：

  Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase

  摘要：

  5'-Adenosine monophosphate-activated protein kinase (AMPK) is a key regulator of mammalian energy homeostasis and has been implicated in mediating many of the beneficial effects of exercise and weight loss including lipid and glucose trafficking. As such, the enzyme has long been of interest as a target for the treatment of Type 2 Diabetes Mellitus. We describe the optimization of beta 1-selective, liver-targeted AMPK activators and their evolution into systemic pan-activators capable of acutely lowering glucose in mouse models. Identifying surrogates for the key acid moiety in early generation compounds proved essential in improving beta 2-activation and in balancing improvements in plasma unbound fraction while avoiding liver sequestration.

  DOI：

  10.1021/acsmedchemlett.7b00417

文献信息

• [EN] PROCESS FOR THE PREPARATION OF IODIDES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'IODURES
  申请人：TECHNION R & D FOUNDATION LTD

  公开号：WO2011154953A1

  公开（公告）日：2011-12-15

  This invention is directed to a process for the preparation of high yield alkyl or aryl iodide from its corresponding carboxylic acid using N-iodo amides.

  这项发明涉及利用N-碘酰胺从相应的羧酸制备高产量的烷基或芳基碘化物的过程。
• [EN] 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 2-[(2-{PHÉNYLAMINO}-1H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]BENZAMIDE EN TANT QU'INHIBITEUR D'IGF-1R POUR LE TRAITEMENT DU CANCER
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009020990A1

  公开（公告）日：2009-02-12

  Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

  新型吡咯吡嘧啶如公式(I)所示，及其药用可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
• [EN] NOVEL METHOD FOR SYNTHESIZING AMANITINS<br/>[FR] NOUVEAU PROCÉDÉ DE SYNTHÈSE D'AMANITINES
  申请人：HEIDELBERG PHARMA GMBH

  公开号：WO2019030171A1

  公开（公告）日：2019-02-14

  The invention relates to novel methods for synthesizing amanitin derivatives having an amino group attached to position 6' of the central tryptophan moiety. The invention furthermore relates to a novel amanitin derivative having an amino group attached to position 6' of the central tryptophan moiety, novel conjugates of such amanitin derivative, and pharmaceutical compositions comprising such conjugates.

  该发明涉及新的方法，用于合成在中心色氨酸部分6'位置带有氨基的鹅膏蕈碱衍生物。此外，该发明还涉及一种新的鹅膏蕈碱衍生物，其中心色氨酸部分6'位置带有氨基，以及这种鹅膏蕈碱衍生物的新结合物，以及包含这种结合物的药物组合物。
• Substituted Morphinans and the Use Thereof
  申请人：Purdue Pharma L.P.

  公开号：US20140187573A1

  公开（公告）日：2014-07-03

  The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4a , and R 4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

  本申请涉及式I化合物： 及其医药可接受的盐和溶剂化物，其中R1、R2、R3、R4a和R4b的定义如说明书中所述。本发明还涉及使用式I化合物来治疗对一或多个阿片受体调节有反应的疾病，或作为合成中间体。本发明中的某些化合物特别适用于治疗疼痛。
• [EN] SUBSTITUTED SILAXANTHENIUM RED TO NEAR-INFRARED FLUOROCHROMES FOR IN VITRO AND IN VIVO IMAGING AND DETECTION<br/>[FR] FLUOROCHROMES ROUGE À PROCHE-INFRAROUGE À BASE D'UN SILAXANTHÉNIUM SUBSTITUÉ POUR L'IMAGERIE ET LA DÉTECTION IN VITRO ET IN VIVO
  申请人：VISEN MEDICAL INC

  公开号：WO2014144793A1

  公开（公告）日：2014-09-18

  The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications.

  这项发明提供了一类荧光化合物。这些化合物是取代硅基蒽离子化合物，可以与一个或多个生物分子（如蛋白质、核酸和治疗性小分子）在化学上连接。这些化合物可用于各种医学、生物学和诊断应用中的成像。这些染料特别适用于体外、体内和体外成像应用。